ScholarIQanswers from OpenAlex & ORCID
Jon M. Wigginton
ResearcherPublications, citations & collaboration network
Jon M. Wigginton is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jon M. Wigginton have?
ScholarIQindexed works
Jon M. Wigginton has 162 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jon M. Wigginton have?
ScholarIQcitation count
Jon M. Wigginton has 34,281 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jon M. Wigginton?
ScholarIQh-index
Jon M. Wigginton has an h-index of 43 in OpenAlex.
What is the i10-index of Jon M. Wigginton?
ScholarIQi10-index
Jon M. Wigginton has an i10-index of 85 in OpenAlex.
What is the OpenAlex record for Jon M. Wigginton?
ScholarIQopenalex
The OpenAlex for Jon M. Wigginton is on the source record.
What are the most-cited papers on Jon M. Wigginton?
ScholarIQmost cited works
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, Wen-Jen Hwu, Suzanne L. Topalian, Patrick Hwu, Charles G. Drake, Luis H. Camacho, John Kauh, Kunle Odunsi, Henry C. Pitot, Omid Hamid, Shailender Bhatia, Renato Martins, Keith D. Eaton, Shuming Chen, Theresa M. Salay, Suresh Alaparthy, Joseph F. Grosso, Alan J. Korman, Susan Parker, Shruti Agrawal, S. Goldberg, Drew M. Pardoll, Ashok Gupta, Jon M. Wigginton
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Scott Gettinger, Leora Horn, Leena Gandhi, David R. Spigel, Scott Antonia, Naiyer A. Rizvi, John D. Powderly, Rebecca S. Heist, Richard D. Carvajal, David M. Jackman, Lecia V. Sequist, David C. Smith, Philip D. Leming, David P. Carbone, Mary Pinder-Schenck, Suzanne L. Topalian, F. Stephen Hodi, Jeffrey A. Sosman, Mario Sznol, David F. McDermott, Drew M. Pardoll, Vindira Sankar, Christoph M. Ahlers, Mark Salvati, Jon M. Wigginton, Matthew D. Hellmann, Georgia Kollia, Ashok Gupta, Julie R. Brahmer